IMMUNOPLANT: Linvo x 4-6 cycles for patients with MRD positivity following induction. Patients then resumed lenalidomide. Essentially 100% MRD negativity rate following linvo consolidation and at 6 months after completion of linvo. This is really a remarkable result and

Kiliminjaro Arms A and E - Etentamig (20 or 40 mg) + Pomalidomide (4 mg). Arm E = step-up dosing and delayed pomalidomide until cycle 2. Grade 5 AEs 9% in Arm A. 0% in Arm E. Apparently lower rates of toxicities in Arm E overall. Arm A: ORR 82% and 18-month PFS 76%. I think

COBRA trial in myeloma - VRd x 8 —> Rd vs KRd x 24 - primary endpoint of PFS and MRD negativity at 12 months - KRd superior as a triplet backbone on both fronts. Now to answer the biggest question - different durations / dose intensity of PI and IMiD Important to note that MRD

I promise (guarantee!) an enlightening talk/discussion on mrd-guided discontinuation of therapy in myeloma! Come to West Hall E2 on 12/7 at 9:30 EST and you can read my thoughts here! https://t.co/ez2JocrKRc

11) LBA3: MajesTEC-3 (B): Tec-Dara vs Dara-Pd/Dara-Vd 📰Patients with 1-3 prior lines and without prior anti-CD38 refractoriness or BCMA exposure were randomized to Tec-Dara vs DPd/DVd. Tec went to q2weeks for cycles 3-6, and q4weeks thereafter. 📊Clear and substantial PFS

10) LBA1: KLN-1010 (Ho et al.) – in-vivo CAR T is coming fast and furious. Here we have (very) preliminary but encouraging results from 3 patients treated with an LD-chemo-free in-vivo-CAR T KLN-1010. The premise is to modify endogenous T-cells to become BCMA-directed CAR T

9) Abstract 919 (Gonzalez et al.) – Peripheral residual disease by ultra-sensitive BloodFlow (circulating tumor cells at 10^-7) and Mass Spec in GEM2017FIT. 😎Among patients who were double-negative PRD, only 5% were MRD positive in BM. Only 4% of patients with 24-month

8) Abstract 693 (Bell et al.) - AT-02 in AL amyloidosis. A pan amyloid-binding Ig fusion that theoretically removes deposits. Not just turning off the spigot, but cleaning up the mess! 👍Enrolled patients with at least a VGPR (i.e., already responded hematologically) but had

7) Abstract 697 (@Myeloma_Doc) – Ph1 LINKER-MM4. Linvo monotherapy +/- transplant. Transplant eligible patients received limited duration linvo; ineligible patients received linvo until progression. 📊ORR 79% but 86% at the 50-200 mg doses. 52% MRD negativity by ITT. No

6) Abstract 269 (Richard et al.) – DURGA-1 study with AZD0120 – same product in RRMM. ⏲️Median time from apheresis to release 14 days and vein-to-vein 28 days. 👍Only 1.4 months follow-up but among 15 evaluable patients, ORR 100% and all MRD evaluable patients were MRD<10^-5.

5) Abstract 258 (Du et al.): GC012F/AZD0120 in newly diagnosed myeloma following 2 cycles of VRd. This dual-targeting BCMA/CD19 FasTCAR led to a 30-month PFS of 88% and 82% sustained MRD negativity, which ranks among the best of outcomes in newly diagnosed MM! 🤔Clearly we are

4) Abstract 256 (@DrKrinaPatel): iMMagine-1 – Anito-cel BCMA CAR T in triple-class exposed RRMM. PFS rate at 18-months 66% which compares mostly favorably with others. No IEC-enterocolitis or atypical neurologic toxicities seen thus far. Most important thing at this point is

3) Abstract 248 (@dikokaz): Could consolidation with a bispecific antibody supplant transplant? IMMUNOPLANT is a ph2 study enrolling patients with MRD positivity after 4+ cycles of induction. 💉Patients received 4-6 cycles of linvoseltamab before maintenance 👍MRD conversion to

2) Abstract 99 (Dytfeld): Disclosure I am an author. The phase 3 COBRA trial compared weekly KRd x 24 cycles vs. VRdx8/Rdx16. Longer course of KRd makes complicates direct comparison but...VRd is hard to administer for long periods of time due to neuropathy (whereas K can be

My top 11 myeloma/amyloidosis abstracts I’m excited about, spanning bispecifics, CAR T, MRD and amyloid clearance. Stay tuned for a much longer discussion at the end re: MajesTEC-3... 1) Abstract 94 (@End_myeloma): CARTITUDE-4 Long-term PFS with cilta-cel in standard-risk

Myeloma / Plasma Cell Dyscrasia ~ #ASH25Top10 (or so) #mmsm #mmMRD #ASH25 - @mtmdphd - DRAFT Update: 12/1/25 - cc @grpetersen1 – @IrenemGhobrial @Taxkourel @RahulBanerjeeMD @AuclairDan @JanakiramMurali @jmikhaelmd @End_myeloma @bdermanmd @szusmani

Great thread on relevant ASH abstracts!

In vivo car t is coming fast and furious! “Here in my car…” 🎶

Next month at #ASH25, we will present first-in-human data of KLN-1010, our novel in vivo CAR-T therapy, from our ongoing Ph 1 inMMyCAR study in a late-breaking oral session. https://t.co/73jxrwsErf

Holy moly est 36-month PFS is over 80%!